Table 2.
Clinical characteristics of patients
| Patient | Age in years | Gender | Disease duration in years | Anti-SSA/Anti-SSB/RF | Extraglandular manifestations | Prednisolone (mg/day) | Adverse events |
| 1a | 59 | Female | 13 | +/+/+ | Arthralgia | - | Vertigo, perspiration |
| 2 | 46 | Female | 12 | +/+/+ | LP, RS | - | GI discomfort, common cold |
| 3a | 50 | Female | 15 | +/+/+ | Arthralgia, RS, LP | - | GI discomfort |
| 4 | 67 | Female | 17 | +/+/+ | Arthralgia, RS | 2.5 | None |
| 5 | 60 | Female | 4 | +/+/+ | Arthralgia, LP, VA | - | GI discomfortb |
| 6a | 61 | Female | 5 | +/+/+ | Arthralgia, LP | - | Pneumonia |
| 7 | 53 | Female | 13 | +/-/+ | LP, PNP | 2.5 | GI discomfort, herpes labialis |
| 8 | 40 | Female | 2 | +/-/- | Arthralgia, LP | - | None |
| 9 | 35 | Female | 12 | +/-/+ | LP, RS | 5 | None |
| 10 | 44 | Female | 9 | +/+/+ | Arthralgia, RS | - | Palpitation, perspirationb |
| 11 | 36 | Female | 2 | +/+/- | Arthralgia | - | Common cold |
aPatients 1, 3, and 6 did not complete the study; bdose was reduced to 720 mg/day after week 12. GI, gastrointestinal; LP, leukopenia; PNP, polyneuropathy; RF, rheumatoid factor; RS, Raynaud syndrome; VA, vasculitis.